Apellis Pharmaceuticals’ (APLS) “Market Perform” Rating Reaffirmed at Raymond James Financial

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “market perform” rating reissued by equities researchers at Raymond James Financial in a note issued to investors on Wednesday,Benzinga reports.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Saturday, February 28th. Roth Mkm assumed coverage on shares of Apellis Pharmaceuticals in a report on Friday, March 13th. They issued a “buy” rating and a $31.00 price target for the company. The Goldman Sachs Group reissued a “sell” rating and issued a $19.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. Mizuho raised their price objective on Apellis Pharmaceuticals from $19.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, March 5th. Finally, Barclays started coverage on Apellis Pharmaceuticals in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $24.00 price objective on the stock. Nine equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $31.89.

Apellis Pharmaceuticals Trading Up 0.4%

Shares of APLS stock traded up $0.17 on Wednesday, reaching $40.40. The company had a trading volume of 12,273,116 shares, compared to its average volume of 4,373,854. The company has a current ratio of 3.14, a quick ratio of 2.70 and a debt-to-equity ratio of 0.98. The stock has a market cap of $5.16 billion, a PE ratio of 310.75 and a beta of 0.26. The company has a 50-day moving average of $21.11 and a 200-day moving average of $22.58. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $40.45.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $199.91 million for the quarter, compared to the consensus estimate of $199.28 million. During the same period last year, the company posted ($0.29) EPS. Apellis Pharmaceuticals’s revenue for the quarter was down 5.9% on a year-over-year basis. On average, equities analysts forecast that Apellis Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Mark Jeffrey Delong sold 3,371 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $73,386.67. Following the sale, the insider owned 78,353 shares of the company’s stock, valued at approximately $1,705,744.81. This trade represents a 4.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Caroline Baumal sold 2,797 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $60,890.69. Following the completion of the sale, the insider owned 86,527 shares in the company, valued at $1,883,692.79. This trade represents a 3.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 115,537 shares of company stock worth $2,486,082. 6.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of APLS. Jones Financial Companies Lllp grew its stake in Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares in the last quarter. Allworth Financial LP raised its stake in shares of Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after purchasing an additional 857 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at approximately $64,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 338.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock valued at $94,000 after buying an additional 4,191 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for $41.00 in cash per share plus a CVR that could add up to $4 per share on SYFOVRE sales milestones — the deal is the primary catalyst for the sharp rise in APLS shares. Biogen to buy Apellis Pharmaceuticals for $5.6 billion
• Neutral Sentiment: Broker reaction: HC Wainwright reaffirmed a “neutral” rating and set a $41 price target (down from $48), which implies little upside versus the acquisition price and signals mixed analyst guidance post‑deal. HC Wainwright rating note
• Neutral Sentiment: Zacks notes that despite heavy volume and the deal news, recent trends in earnings estimate revisions could limit sustainable upside unless fundamentals or deal certainty improve. Apellis Moves 135.4% Higher: Will This Strength Last?
• Negative Sentiment: Multiple shareholder law firms announced investigations (Kahn Swick & Foti, Halper Sadeh, Ademi LLP) questioning whether Apellis shareholders are receiving a fair price/process in the sale — potential legal challenges or disclosure fights could delay closing or add deal uncertainty. KSF investor alert
• Negative Sentiment: Analyst downgrades and target cuts around the deal: Needham cut APLS from “buy” to “hold” and Cantor Fitzgerald trimmed its target previously — these actions reflect mixed views on deal premium and post‑close expectations. Cantor Fitzgerald cuts PT on Apellis

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.